Emyria Ltd (ASX:EMD) managing director Dr Michael Winlo joins Elisha Newell from Proactive to talk about receiving approval from the Human Research Ethics Committee (HREC ) to start a Phase 3 clinical trial of its ultra-pure cannabidiol (CBD) candidate, EMD-RX5. Once the trial is successfully completed, EMD-RX5 will be registered with Therapeutic Goods Administration (TGA) as a Schedule 3, over-the-counter treatment (OTC) for the symptoms of psychological distress. Dr Winlo goes on to discuss the company's plans for the rest of 2022.
Emyria approved to start Phase 3 clinical trial of EMD-RX5
